Johnson & Johnson vs Sony Group Corp — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Johnson & Johnson is far larger — about 4.5× Sony Group Corp's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Sony Group Corp for 96 Days on average.
| JNJ | SONY | |
|---|---|---|
Market Cap | $618.09B | $136.87B |
Volume | 6,050,983 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $278.43 | $30.26 |
52-Week Low | $186.00 | $19.32 |
Typical Hold Time | 129 Days | 96 Days |
Enterprise Value | $646.37B | $134.77B |
Dividend Yield | 2.09% | 0.66% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Sony trades at $24.12, up 2.55% today, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly results with two beats and one miss, while full-year 2025 showed strong revenue of $12.96T and net income of $1.14T. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations, though 2026 projections indicate potential profitability challenges with negative net income margins.
Sony presents a compelling value opportunity with reasonable valuation metrics (P/E 20.34, P/S 1.79) and strong cash flow generation, but faces headwinds from projected 2026 profitability decline. The entertainment and technology conglomerate benefits from diverse revenue streams and intellectual property strength, though investors should monitor execution risks amid competitive pressures and macroeconomic uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →